Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist stethoscope and data flow icon representing AI in healthcare

Jul 16, 2026

FPT Launches MediSight Framework to Accelerate AI-Driven Healthcare and Life Sciences Innovation

FPT has unveiled MediSight, an innovative AI framework aimed at transforming healthcare and life sciences through enhanced digital capabilities.The MediSight framework is designed to assist healthcare providers, medical device manufacturers, and pharmaceutical companies in accelerating their digital transformation efforts. It combines autonomous AI digital workers with healthcare-specific applications, enabling organizations to streamline clinical, operational, and regulatory workflows. This int
A stethoscope on a medical chart in a dimly lit consultation room.

Jul 16, 2026

‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1

Digital health startups have experienced a significant uptick in fundraising, with $7.4 billion raised in the first half of 2026, surpassing the $6.4 billion raised in the same period last year. This growth is reflected in the number of deals, which remained stable at 244, but the nature of the investments has shifted towards larger amounts, with megadeals (valued at $100 million or more) constituting 45% of total funding.The median deal size has reached $14 million, marking the highest level si
A minimalist illustration of a surgical robot arm and scalpel on a dark background.

Jul 16, 2026

Japan overhauls healthcare and life sciences with Nvidia AI

Japan is set to revolutionize its healthcare and life sciences sectors through the integration of AI technologies, particularly leveraging Nvidia's innovations.Recent discussions led by Nvidia CEO Jensen Huang highlighted Japan's commitment to advancing medical technology with AI-driven solutions. The country is actively implementing autonomous surgical robots, AI-enhanced imaging systems, and innovative drug discovery platforms. A notable initiative is the Tokyo-1 consortium, which unites major
A laboratory vial containing a drug compound in a dimly lit lab setting.

Jul 15, 2026

Bora Pharmaceuticals and Insilico Medicine Strike a $2.5 Billion AI Alliance

Bora Pharmaceuticals and Insilico Medicine have entered a significant partnership aimed at revolutionizing AI-driven drug development, with a potential value exceeding $2.5 billion.This collaboration, announced during BIO Asia-Taiwan, marks a pivotal shift in the pharmaceutical landscape, focusing on integrating AI not just in drug discovery but also in manufacturing processes. Insilico's Pharma.AI platform, which encompasses tools for target discovery and clinical insights, will be paired with
A minimalist illustration of a bioreactor representing biomanufacturing.

Jul 15, 2026

Europe widens biomanufacturing gap between EU and US

A recent report from GlobalData highlights a significant widening of the biomanufacturing gap between the US and the EU, with European facilities increasingly favored for drug manufacturing contracts. The analysis indicates that over 50% of new drugs in 2025 were associated with European manufacturing sites, a notable increase from just 25% in 2023. In contrast, the US's share of newly approved drug contracts has stagnated at approximately 18% since 2024. This trend reflects a strategic shift in
A medical chart and stethoscope in a dimly lit hospital room

Jul 15, 2026

Statement – Govern AI in health before the gaps become irreversible

The urgent need for AI governance in healthcare was highlighted during a recent statement in Lisbon, emphasizing the disparity between AI deployment and its regulation.Despite a growing adoption of AI technologies in healthcare—such as diagnostics and patient chatbots—only 8% of countries in the WHO European Region have a dedicated AI strategy. This stark contrast raises concerns as nearly two-thirds of these countries are already utilizing AI, underscoring a significant gap in governance. The W
Clinical trial paperwork on a desk in a research office

Jul 15, 2026

How well are AI-discovered drugs faring in the clinic?

The performance of AI-discovered drugs in clinical settings is generating significant interest, particularly given the traditionally lengthy and costly drug development process, which can exceed $2.6 billion and take up to 15 years. While AI has been heralded as a transformative force in drug R&D, the actual success of AI-generated drugs remains uncertain.Currently, only a handful of AI-discovered drugs have entered clinical trials, with those that have shown a higher success rate in phase 1 com
A minimalist illustration of a pill and a factory, symbolizing pharmaceutical manufacturing.

Jul 15, 2026

Generative AI Moves From Drug Discovery to Drug Factories in $2.5B Bora Deal

Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance to integrate generative AI technologies into pharmaceutical manufacturing, potentially valued at over $2.5 billion. This partnership aims to extend AI's role, which has predominantly been in drug discovery, into the more complex realm of drug production.The collaboration focuses on leveraging Insilico's AI platforms, PandaOmics and Chemistry42, which have been instrumental in identifying drug targets and designing molecu
A tissue sample on a microscope slide in a dimly lit lab

Jul 15, 2026

Global AI in Pathology Market Poised for Phenomenal Expansion at a CAGR of ~25% by 2034 | DelveInsight

The AI in pathology market is on track for remarkable growth, anticipated to reach a compound annual growth rate (CAGR) of approximately 25% by 2034. This surge is largely attributed to the increasing integration of digital pathology and the rising incidence of cancer, alongside a demand for more efficient and precise diagnostic processes.Factors propelling this expansion include significant investments in healthcare digitalization and the favorable regulatory environment that supports the adopt
A T-cell engager on a lab bench in a dimly lit laboratory

Jul 15, 2026

Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

VERAXA Biotech is poised to leverage artificial intelligence in its drug discovery efforts, particularly through a new partnership with Ardigen, an AI-focused contract research organization.This collaboration aims to enhance the development of VERAXA’s BiTAC(R) cancer therapy platform by utilizing AI to identify effective dual-target combinations for T-cell engagers and antibody-drug conjugates. By integrating Ardigen's expertise in computational biology with VERAXA’s antibody engineering, the p
A minimalist representation of a TNIK inhibitor molecule in a dark color scheme.

Jul 15, 2026

Insilico & Bora Partner on AI Drug Discovery

Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance aimed at enhancing AI-driven drug discovery and development.The partnership leverages Insilico's Pharma.AI platform, which integrates target identification, generative chemistry, and multi-parameter optimization. Since its inception in 2021, this platform has successfully generated 31 preclinical candidates, with 13 receiving IND approvals. Notably, one standout asset is ISM018_055, an AI-generated TNIK inhibitor current
A minimalist illustration of a box and pallet symbolizing pharmaceutical logistics.

Jul 15, 2026

Q&A: How Pharma 3PL Is Evolving Beyond the Pallet

The landscape of third-party logistics (3PL) in the pharmaceutical sector is undergoing significant transformation, driven by the rise of personalized medicine and the complexities of modern therapies.As the industry pivots towards smaller patient populations and intricate therapies, 3PL providers are re-evaluating their operational frameworks. The ongoing development of over 4,000 gene, cell, and RNA therapies necessitates a higher level of logistical accuracy and coordination than traditional